-+ 0.00%
-+ 0.00%
-+ 0.00%

Intellia to report Phase 3 HAELO trial topline data for lonvo-z on April 27

PUBT·04/24/2026 20:05:28
Listen to the news
Intellia to report Phase 3 HAELO trial topline data for lonvo-z on April 27
  • Intellia set April 27, 2026 for release of topline results from global Phase 3 HAELO trial of lonvoguran ziclumeran in hereditary angioedema.
  • Data have not yet been presented; company scheduled webcast at 8:00 a.m. ET on April 27, 2026.
  • Readout is positioned as first Phase 3 results for an in vivo CRISPR gene-editing candidate, a potential milestone for clinical validation of its platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604241605PRIMZONEFULLFEED9696794) on April 24, 2026, and is solely responsible for the information contained therein.